Rosetta Genomics
Interpace Diagnostics Q3 Revenues Up 38 Percent
The company beat the consensus Wall Street estimate on the top line and guided to 2018 revenues of between $21 million and $22 million.
Rosetta Genomics Files for Chapter 7 Bankruptcy
Rosetta had disclosed that it intended to file for bankruptcy after its merger with Genoptix was not completed as planned.
Rosetta Genomics Dispute With Genoptix Places Pending Merger in Jeopardy
The merger, which was previously scuttled and later revived with Rosetta shareholder approval, was due to close on May 27.
Rosetta Genomics Shareholders Approve Genoptix Merger
Upon completion of the transaction, Rosetta will become a privately held subsidiary of Genoptix and its shares will cease to trade on the Nasdaq.
Genoptix Inks Distribution Deal for Rosetta Genomics' Testing Services
The deal comes as the firms try — for the second time — to close a merger that had previously failed to gain necessary approval from Rosetta shareholders.
Feb 28, 2018
Rosetta Genomics, Genoptix Sign New Merger Agreement
Feb 23, 2018
Rosetta Genomics, Genoptix Merger Terminated
Dec 15, 2017
Genoptix to Acquire Rosetta Genomics for $10M
Sep 28, 2017
Rosetta Genomics Initiates $2M Private Placement
Sep 5, 2017
Rosetta Genomics Announces Layoffs
Mar 30, 2017
Rosetta Genomics Q4 Revenues Drop 44 Percent
Mar 16, 2017
Rosetta Genomics Announces Reverse Stock Split
Feb 23, 2017
Rosetta Genomics Completes Private Placement Tranche
Dec 20, 2016